The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 26, 2025 for Aayush Agrawal, ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Midcap 150 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aayush Agrawal, promoter and trustee of the Aayush Agrawal Trust, has created a pledge on 1,70,000 shares (0.14% of total share capital) of Ajanta Pharma Ltd on November 19, 2025. The reason stated is to raise a new loan, with Bajaj Finance Ltd as the lender. After this pledge, the total encumbered shares held by the Aayush Agrawal Trust stand at 67,50,002 shares, or 5.40% of the company's share capital. The trust's overall promoter holding remains at 1,41,12,924 shares (11.30%). Other promoter-group entities such as the Ravi P Agrawal Trust (4.85% encumbered) also have existing pledged shares. This is a routine encumbrance disclosure filed under SEBI SAST Regulations.
This is a small pledge creation by a single promoter entity and is unlikely to materially impact the stock price. It signals the promoter is using a small portion of their holdings as collateral for personal borrowing, which is common but worth tracking if additional pledges are created in the future.